Nanorepro: New revenue guidance reinforces growth trajectory; chg. est. - NuWays AG Research
Ahead of its AGM today, NanoRepro published group revenue guidance for the short-, medium- and
long-term on Friday, providing greater visibility on the expected growth trajectory of its multi-brand
health platform. In detail:
ANNONS
FY26 guidance confirms double-digit growth. Management guided for ~ € 18m in revenue, slightly below our projection of € 19m (eNuW), but still confirming solid double-digit growth of ~ 12.5% yoy. Growth is expected to be largely organic, as the current inorganic contribution from ALPHABIOL should remain modest at ~ € 0.2m (eNuW) in FY26e.